The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats

Veterinary Journal

Volumn 183, Issue 3, 2010, Pages 355-357

  Furrer, Daniela ^a   Kaufmann, Karin ^b   Tschuor, Flurin ^b   Reusch, Claudia E ^b   Lutz, Thomas A ^a  

^a VETSUISSE FACULTY UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cat; Diabetes mellitus; Dipeptidyl peptidase IV; Glucagon; Glucagon like peptide 1

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; EXPERIMENTAL CAT; FOLLOW UP; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MEAL; NONHUMAN;

ANIMALS; CATS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; NITRILES; PYRROLIDINES;

FELIDAE;

EID: 75849142837     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2008.11.017     Document Type: Article

References (11)

1. Ahrén B., and Hughes T.E. Inhibition of dipeptidyl peptidase IV augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 146 (2005) 2055-2059
2. Ahrén B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.A., Sandqvist M., Bavenholm P., Efendic S., Eriksson J.W., Dickinson S., and Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 (2002) 869-875
3. Balkan B., Kwasnik L., Miserendino R., Holst J.J., and Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42 (1999) 1324-1331
4. Hoenig M., Alexander S., Holson J., and Ferguson D.C. Influence of glucose dosage on interpretation of intravenous glucose tolerance tests in lean and obese cats. Journal of Veterinary Internal Medicine 16 (2002) 529-532
5. Holst J.J. Therapy of type 2 diabetes mellitus based on the actions of the glucagons-like peptide-1. Diabetes/Metabolism Research and Reviews 18 (2002) 430-441
6. Nauck M.A. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetologica 35 (1998) 117-129
7. Nielsen L.L., Young A.A., and Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regulatory Peptides 117 (2004) 77-88
8. Ritzel R., Orskov C., Holst J.J., and Nauck M.A. Pharmacokinetic, insulinotropic and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 38 (1995) 720-725
9. Seldinger S.I. Catheter replacement of the needle in percutaneous arteriography. Acta Radiologica 39 (1953) 368-376
10. Tschuor F., Furrer D., Kaufmann K., Lutz T.A., and Reusch C.E. Intravenous arginine stimulation test in cats with transient and non-transient diabetes mellitus. Journal of Veterinary Internal Medicine 20 (2006) 725-726
11. Zini, E., Osto, M., Franchini, M., Guscetti, F., Donath, M.Y., Perren, A., Heller, R.S., Linscheid, P., Bouwman, M., Ackermann, M., Lutz, T.A., Reusch, C.E., 2008. Hyperglycaemia but not hyperlipidaemia causes beta-cell dysfunction and beta-cell loss in the domestic cat. Diabetologia, doi:10.1007/s00125-008-1201-y.